Expert Opinion

Original Research: Expert Opinion on Investigational Drugs

Contributions are welcomed in the form of: Full-length primary research papers reporting the original results of clinical investigations on agents that are in Phase I and II clinical trials. Results of Phase I and II clinical studies of drugs previously launched for another indication. Studies on drugs that are under review for NDA or have… Read more »

Original Research: Expert Opinion on Drug Safety

Contributions are welcomed in the form of: Full-length primary research papers reporting the original results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes. Methods for the detection and evaluation of drug-associated adverse events. Prior publication: Expert Opinion will only consider work that has not been previously published in full…. Read more »

Original Research: Expert Opinion on Drug Delivery

Contributions are welcomed in the form of: Delivery technologies, vehicles, formulations and devices The delivery of specific drugs and therapeutic classes Modes of entry into the body and applications in certain diseases and disorders Prior publication: Expert Opinion will only consider work that has not been previously published in full. Abstract, poster or oral presentations… Read more »

Original Research: Expert Opinion on Biological Therapy

Contributions are welcomed in the form of: Full-length primary research papers reporting the original results of clinical investigations on biological agents that are in Phase III and IV clinical trials. Studies on drugs that are under review for NDA or have been granted Orphan Drug Status. Biotherapeutic-based studies with a strong link to clinical practice,… Read more »

Drug Evaluation: Expert Opinion on Drug Metabolism & Toxicology

Scope: Drug Evaluations focus on providing an independent perspective on the metabolism and toxicology of a specific drug, and the impact this has on the clinical efficacy. Word limit: The word limit for Drug Evaluations is 3,000 words (not including tables, figures and references). Peer review: All articles are subject to rigorous peer-review by 2-3… Read more »

Drug Evaluation: Expert Opinion on Investigational Drugs

Scope: Drug Evaluations will present an evaluated overview of the clinical experience with the compound that is in Phase II clinical trials. Although discussion should encompass basic pharmacology and pharmacokinetics, the primary focus of the review should be the clinical efficacy of the compound. Word limit: The word limit for Drug Evaluations is 3,000 words… Read more »

Drug Evaluation: Expert Opinion on Orphan Drugs

Scope: Drug Evaluations will present an evaluated overview of the clinical experience with the biologic compound. Although discussion should encompass basic pharmacology and pharmacokinetics, the primary focus of the review should be the clinical efficacy of the compound. For launched compounds the information should be limited to approved indications and avoid off-label discussion. Peer review:… Read more »

Drug Evaluation: Expert Opinion on Biological Therapy

Scope: Drug Evaluations will present an evaluated overview of the clinical experience with the biologic compound. Although discussion should encompass basic pharmacology and pharmacokinetics, the primary focus of the review should be the clinical efficacy of the compound. For launched compounds the information should be limited to approved indications and avoid off-label discussion. Peer review:… Read more »

Review Article: Expert Opinion on Emerging Drugs

Scope: Expert Opinion on Emerging Drugs was devised to provide an expert evaluation of the most important emerging drug technologies. These are assessed in terms of their potential impact on the current management of specific diseases. Many sources of information on compounds in development are available to research and development decision makers, but none of… Read more »

Technology Evaluation

Word limit: The word limit for Technology Evaluations is 3,000-5,000 words (not including figures, tables and references). Every article must contain: Title: Should be concise but informative, including the drug and therapeutic indication. Titles should not contain brand names. Authors’ names and addresses: Including address, academic qualifications and job titles of all authors, as well as… Read more »